Page last updated: 2024-09-05

hydromethylthionine and Disease Exacerbation

hydromethylthionine has been researched along with Disease Exacerbation in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Bartochowski, Z; Grossberg, GT; Hashweh, NN; Khoury, R1
Baddeley, TC; Bentham, P; Bracoud, L; Ganesan, H; Gauthier, S; Hammel, J; Hardlund, J; Harrington, CR; Jia, J; Kipps, CM; Kook, K; Moebius, HJ; Murray, AD; Riedel, G; Rubino, CM; Schelter, BO; Shiells, H; Staff, RT; Storey, JMD; Vuksanovic, V; Wischik, CM; Wischik, DJ1

Reviews

1 review(s) available for hydromethylthionine and Disease Exacerbation

ArticleYear
An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease.
    Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:6

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognitive Dysfunction; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Humans; Methylene Blue; Protein Aggregates; Randomized Controlled Trials as Topic; tau Proteins; Treatment Outcome

2020

Trials

1 trial(s) available for hydromethylthionine and Disease Exacerbation

ArticleYear
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.
    Journal of Alzheimer's disease : JAD, 2020, Volume: 75, Issue:2

    Topics: Adult; Aged; Atrophy; Brain; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Frontotemporal Dementia; Humans; Magnetic Resonance Imaging; Male; Methylene Blue; Middle Aged; Treatment Outcome

2020